Search - tctmd.com

Displaying 21 - 40 of 641

Sort: Relevancy | Date

Presentation TCT 2016

Hybrid Coronary Revascularization: Rationale, Procedure Alternatives, and Technical Considerations

Presenter: John D. Puskas, Gregg W. Stone, John S. Douglas Jr

November 01, 2016

Presentation TCT 2016

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, Pamela S. Douglas

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation TCT 2016

SENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Presenter: Gregg W. Stone, Philippe Pibarot, Susheel K. Kodali

November 01, 2016

Presentation TCT 2016

When There Are No Revascularization Options: Indications and Evidence for the Coronary Sinus Reducer in the CHIP Patient

Presenter: Jonathan M. Hill, Dimitri Karmpaliotis, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

Benefit of Supersaturated Oxygen for Large Anterior STEMI: From ICI-HOT to Approval?

Presenter: Cindy L. Grines, Holger Thiele, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

EXCEL Top Line Results Revisited

Presenter: A. Pieter Kappetein, Marie-Claude Morice, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

Key Note Lecture II. Regulatory Reform of Medical Device Approvals by the European Commission Motivating Factors, Anticipated Changes, and Timelines

Presenter: Matthew G. Hillebrenner, Gregg W. Stone, Alan G. Fraser

October 31, 2016

Presentation TCT 2016

Key Note Lecture I. FDA/CDRH State of the Union

Presenter: Matthew G. Hillebrenner, Gregg W. Stone, Jeffrey Shuren

October 31, 2016

Presentation TCT 2016

The FDA Town Hall Meeting: Evolution of a Decades Long Collaboration Between Physician-Scientists, Industry, Regulators, and Payors

Presenter: Matthew G. Hillebrenner, Gregg W. Stone

October 31, 2016

News Industry News

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

October 31, 2016

News Conference News TCT 2016

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Michael O'Riordan

October 31, 2016

Presentation TCT 2016

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone

October 31, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

Presentation TCT 2016

Update on RCTs in FMR, and First Report of the COAPT Roll-in Patients

Presenter: Alec S. Vahanian, Ralph Stephan von Bardeleben, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Should Clinical Trial Interpretation Be Dominated by A P Value of 0.05 for the Primary Endpoint?

Presenter: Peter Juni, E. Magnus Ohman, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Gregg W. Stone

October 30, 2016

Advertisement

Hybrid Coronary Revascularization: Rationale, Procedure Alternatives, and Technical Considerations

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

SENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

When There Are No Revascularization Options: Indications and Evidence for the Coronary Sinus Reducer in the CHIP Patient

Benefit of Supersaturated Oxygen for Large Anterior STEMI: From ICI-HOT to Approval?

EXCEL Top Line Results Revisited

Key Note Lecture II. Regulatory Reform of Medical Device Approvals by the European Commission Motivating Factors, Anticipated Changes, and Timelines

Key Note Lecture I. FDA/CDRH State of the Union

The FDA Town Hall Meeting: Evolution of a Decades Long Collaboration Between Physician-Scientists, Industry, Regulators, and Payors

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

Update on RCTs in FMR, and First Report of the COAPT Roll-in Patients

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Should Clinical Trial Interpretation Be Dominated by A P Value of 0.05 for the Primary Endpoint?

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content